Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H, Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. Shariat SF, et al. Among authors: serretta v. J Urol. 2006 Sep;176(3):919-26; discussion 926. doi: 10.1016/j.juro.2006.04.017. J Urol. 2006. PMID: 16890655
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Shariat SF, et al. Among authors: serretta v. J Urol. 2005 May;173(5):1518-25. doi: 10.1097/01.ju.0000154696.48217.75. J Urol. 2005. PMID: 15821471
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, Shariat SF. Hutterer GC, et al. Among authors: serretta v. BJU Int. 2008 Mar;101(5):561-5. doi: 10.1111/j.1464-410X.2007.07352.x. BJU Int. 2008. PMID: 18257856
Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer.
Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M. Cantiello F, et al. Among authors: serretta v. Eur Urol Oncol. 2018 Oct;1(5):403-410. doi: 10.1016/j.euo.2018.06.006. Epub 2018 Jul 13. Eur Urol Oncol. 2018. PMID: 31158079
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, Cimmino A, Di Stasi S, Musi G, Hurle R, Serretta V, Busetto GM, De Berardinis E, Cioffi A, Perdonà S, Borghesi M, Schiavina R, Cozzi G, Almeida GL, Bove P, Lima E, Grimaldi G, Matei DV, Crisan N, Muto M, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Shariat S, Mirone V, Lucarelli G. Ferro M, et al. Among authors: serretta v. World J Urol. 2019 Mar;37(3):507-514. doi: 10.1007/s00345-018-2397-1. Epub 2018 Jul 10. World J Urol. 2019. PMID: 29992381
Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Gontero P, et al. Among authors: serretta v. Eur Urol. 2015 Jan;67(1):74-82. doi: 10.1016/j.eururo.2014.06.040. Epub 2014 Jul 16. Eur Urol. 2015. PMID: 25043942 Free article.
Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, Perdona S, Verze P, La Rocca R, Borghesi M, Schiavina R, Brunocilla E, Almeida GL, Bove P, Lima E, Grimaldi G, Autorino R, Crisan N, Abu Farhan AR, Battaglia M, Serretta V, Russo GI, Morgia G, Terracciano D, Musi G, de Cobelli O, Mirone V, Shariat SF. Vartolomei MD, et al. Among authors: serretta v. Clin Genitourin Cancer. 2018 Dec;16(6):445-452. doi: 10.1016/j.clgc.2018.07.003. Epub 2018 Jul 6. Clin Genitourin Cancer. 2018. PMID: 30077463
142 results